Source: FinanzNachrichten

Reprieve Cardiovascular: Reprieve Cardiovascular, Inc.: First-In-Human Study Demonstrates the Potential of the Reprieve System in Patients with Acute Decompensated Heart Failure

--Results Presented at CSI Focus D-HF Meeting Show Safe, Rapid Fluid and Sodium Removal, Highlighting Potential New Approach to Manage Acute Decompensated Heart Failure-- Reprieve Cardiovascular, ...

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Mark Pacyna's photo - CEO of Reprieve Cardiovascular

CEO

Mark Pacyna

CEO Approval Rating

90/100

Read more